Enhancement of the Immunogenicity and Protective Efficacy of a Mucosal Influenza Subunit Vaccine by the Saponin Adjuvant GPI-0100

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Liu, Heng ^a   Patil, Harshad P ^a   de Vries Idema, Jacqueline ^a   Wilschut, Jan ^a   Huckriede, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GPI 0100; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 4; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNOGENICITY; INFLUENZA; LOW DRUG DOSE; LUNG ALVEOLUS MACROPHAGE; MOUSE; MUCOSAL IMMUNITY; NEUTROPHIL COUNT; NONHUMAN; TH2 CELL; VIRUS INHIBITION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; FEMALE; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MUCOUS MEMBRANE; ORTHOMYXOVIRIDAE INFECTIONS; SAPONINS; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SUBUNIT;

MURINAE; MUS; ORTHOMYXOVIRIDAE;

EID: 84871284434     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052135     Document Type: Article

References (46)

1. Brandtzaeg P, (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25: 5467-84.
2. Brandtzaeg P, (2009) Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 70: 505-15.
3. Brandtzaeg P, Farstad IN, Johansen FE, Morton HC, Norderhaug IN, et al. (1999) The B-cell system of human mucosae and exocrine glands. Immunol Rev 171: 45-87.
4. Amorij JP, Hinrichs WL, Frijlink HW, Wilschut JC, Huckriede A, (2010) Needle-free influenza vaccination. Lancet Infect Dis 10: 699-711.
5. Sharma S, Mukkur TK, Benson HA, Chen Y, (2009) Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 98: 812-43.
6. Pavot V, Rochereau N, Genin C, Verrier B, Paul S, (2012) New insights in mucosal vaccine development. Vaccine 30: 142-54.
7. Block SL, (2004) Role of influenza vaccine for healthy children in the US. Paediatr Drugs 6: 199-209.
8. Jabbal-Gill I, (2010) Nasal vaccine innovation. J Drug Target 18: 771-86.
9. Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM, (2004) Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 3: 643-54.
10. Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, et al. (2007) A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 25: 5367-73.
11. Boyce TG, Hsu HH, Sannella EC, Coleman-Dockery SD, Baylis E, et al. (2000) Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19(2-3): 217-26.
12. Neutra MR, Kozlowski PA, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-58.
13. Lawson LB, Norton EB, Clements JD, (2011) Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 23: 414-20.
14. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350: 896-903.
15. Couch RB, (2004) Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med 350: 860-1.
16. Marciani DJ, Press JB, Reynolds RC, Pathak AK, Pathak V, et al. (2000) Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 18: 3141-51.
17. Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K, May RD, (2003) Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine 21: 3961-71.
18. Ragupathi G, Yeung KS, Leung PC, Lee M, Lau CB, et al. (2008) Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine 26: 4860-5.
19. Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, et al. (2005) A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine 23: 3114-22.
20. Liu H, Bungener L, ter Veer W, Coller BA, Wilschut J, et al. (2011) Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. Vaccine 29: 2037-43.
21. Zhang P, Yang QB, Marciani DJ, Martin M, Clements JD, et al. (2003) Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis. Vaccine 21: 4459-71.
22. Peterson GL, (1997) A simplification of the protein assay method of Lowryet al. which is more generally applicable. Anal Biochem 83: 346-56.
23. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, et al. (2008) Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26: 2350-9.
24. Brandt C, Power UF, Plotnicky-Gilquin H, Huss T, Nguyen T, et al. (1997) Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. J Infect Dis 176: 884-91.
25. Plotnicky-Gilquin H, Goetsch L, Huss T, Champion T, Beck A, et al. (1999) Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J Virol 73: 5637-45.
26. Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, et al. (2010) A whole virus pandemic influenza H1N1 vaccine is highly immunoenic and protective in active immunization and passive protection mouse models. PLoS One 5: e9349.
27. Persson CG, Erjefalt JS, Greiff L, Erjefalt I, Korsgren M, et al. (1998) Contribution of plasma-derived molecules to mucosal immune defence, disease and repair in the airways. Scand J Immunol 47: 302-13.
28. Renegar KB, Small PA Jr, Boykins LG, Wright PF, (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173: 1978-86.
29. Constant SL, Brogdon JL, Piggott DA, Herrick CA, Visintin I, et al. (2002) Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. J Clin Invest 110: 1441-8.
30. Constant SL, Lee KS, Bottomly K, (2000) Site of antigen delivery can influence T cell priming: pulmonary environment promotes preferential Th2-type differentiation. Eur J Immunol 30: 840-7.
31. Bienenstock J, McDermott MR, (2005) Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 206: 22-31.
32. Yamamoto M, Vancott JL, Okahashi N, Marinaro M, Kiyono H, et al. (1996) The role of Th1 and Th2 cells for mucosal IgA responses. Ann N Y Acad Sci 778: 64-71.
33. Minne A, Louahed J, Mehauden S, Baras B, Renauld JC, et al. (2007) The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 122: 316-25.
34. Vujanic A, Sutton P, Snibson KJ, Yen HH, Scheerlinck JP, (2012) Mucosal vaccination: Lung versus nose. Vet Immunol Immunopathol 148: 172-7.
35. Sanders MT, Deliyannis G, Pearse MJ, McNamara MK, Brown LE, (2009) Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine 27: 2475-82.
36. Southam DS, Dolovich M, O'Byrne PM, Inman MD, (2002) Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 282: L833-9.
37. Coulter A, Harris R, Davis R, Drane D, Cox J, et al. (2003) Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 21: 946-9.
38. Wee JL, Scheerlinck JP, Snibson KJ, Edwards S, Pearse M, et al. (2008) Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol 1: 489-96.
39. Vujanic A, Snibson KJ, Wee JL, Edwards SJ, Pearse MJ, et al. (2012) Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine. Clin Vaccine Immunol 19: 79-83.
40. Lycke N, (2012) Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12: 592-605.
41. Hagiwara Y, Komase K, Chen Z, Matsuo K, Suzuki Y, et al. (1999) Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine. Vaccine 17: 2918-26.
42. Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, et al. (2005) Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J Med Virol 75: 130-6.
43. Brandtzaeg P, Farstad IN, Haraldsen G, (1999) Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today 20: 267-77.
44. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, et al. (2002) Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 168: 2930-8.
45. Mbawuike IN, Pacheco S, Acuna CL, Switzer KC, Zhang Y, et al. (1999) Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J Immunol 162: 2530-7.
46. Vujanic A, Wee JL, Snibson KJ, Edwards S, Pearse M, et al. (2010) Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens. Vaccine 28: 2593-7.